Quality of life in schizophrenic patients

Dialogues in Clinical Neuroscience

Volumn 9, Issue 2, 2007, Pages 215-226

  Bobes, Julio ^a   Garcia Portilla, Maria Paz ^a   Bascaran, Maria Teresa ^a   Saiz, Pilar Alejandra ^a   Bousoño, Manuel ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Antipsychotic; Quality of life; Schizophrenia; Side effect

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESEARCH; DRUG USE; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FUNCTIONAL STATUS; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; LOW DRUG DOSE; MENTAL DISEASE; PATIENT ASSESSMENT; PATIENT CARE; POLYURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SEXUAL DYSFUNCTION; SLEEP DISORDER; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UNSPECIFIED SIDE EFFECT;

ACTIVITIES OF DAILY LIVING; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; MOOD DISORDERS; PATIENT SATISFACTION; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 34447547503     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. The WHOQOL Group. The World Health Organization Quality of Life Assessment (the WHOQOL): position paper from the World Health Organisation. Soc Sci Med. 1995;41:1403-1409.
2. Bobes J, Garcia-Portilla MP. Quality of life in schizophrenia. In: Katschnig H, Freeman H, Sartorius N, eds. Quality of Life in Mental Disorders. Chichester, UK: John Wiley & Sons Ltd; 2005:153-168.
3. Bobes J. Current status of quality of life assessment in schizophrenic patients. Eur Arch Psychiatry Clin Neurosc. 2001;251(suppl 2):II/38-II/42.
4. Bobes J, Garcia-Portilla MP, Saiz PA, Bascaran T, Bousoño M. Quality of life measures in schizophrenia. Eur Psychiatry. 2005;20:S313-S317.
5. Lehman AF, Postrado LT, Rachoba LT. Convergent validation of quality of life assessment for persons with severe mental illness. Qual Life Res. 1993;2:327-333.
6. Browne S, Roe M, Lane A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand. 1996;94:118-124.
7. Skantze K, Malm U, Dencker SJ, May PR, Corrigan P. Comparison of quality of life with standard of living in schizophrenic outpatients. Br J Psychiatry. 1992;161: 797-801.
8. Lehman AF. The well-being of chronic mental patients: assessing their quality of life. Arch Gen Psychiatry. 1983;40:369-373.
9. Lehman AF. The effects of psychiatric symptoms on quality of life assessments among the chronically mentally ill. Eval Prog Planning. 1983;6:143-151.
10. Sainfort F, Becker M, Diamond R. Judgments of quality of life of individuals with severe mental disorders: patient self-report versus provider perspectives. Am J Psychiatry. 1996;153:497-502.
11. Becker M, Diamond R, Sainton F. A new patient focused index for measuring quality of life in persons with severe and persistent mental illness. Qual Life Res. 1993;2:239-251.
12. Awad AG, Voruganti LNP, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res. 1997;6:21-26.
13. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50:79-88.
14. Carrière P, Bonhomme D, Lemperiere T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicenter, double-blind study (the Amisulpride Study Group). Eur Psychiatry. 2000;15:321-329.
15. Colonna L, Saleem P, Dondey-Nouvel L, Rein W, and the Amisulpride Study Group. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacol. 2000;15:13-22.
16. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalised patients with refractory schizophrenia. N Engl J Med. 1997;337:809-815.
17. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull. 1996;32:683-697.
18. Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Comm Psychiatry. 1990;41:892-897.
19. Strakowski SM, Johnson JL, Delbello MP, et al. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophr Res. 2005;78:161-169.
20. Naber D, Riedel M, Klimke A et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand. 2005;111:106-115.
21. Giner J, Bobes J, Cervera S, Leal C, Baca E, Ibáñez E. Impact of olanzapine on quality of life of patients with schizophrenia: one-year follow-up with the Seville Quality of Life Questionnaire. Actas Esp Psiquiatr. 2004;32:1-7.
22. Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. 1999;8:417-426.
23. Hamilton SH, Revicki DA, Genduso LA, Beasley CM. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology. 1998;18:41-49.
24. Montes JM, Ciudad A, Gascón J, Gómez JC, and the EFESO Study Group. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog Neuro-Psychopharmacol Biol Psychiatry. 2003;27:667-674.
25. Gureje O, Miles W, Keks N, et al. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res. 2003;61:303-314.
26. Ritchie CW, Chiu E, Harrigan S, et al. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry. 2003;18:432-440.
27. Voruganti L, Cortese L, Owyeumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res.. 2002;57:201-208.
28. Ho BC, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry. 1999;60:658-663.
29. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorder. J Clin Psychopharmacol. 1997;17:407-418.
30. Hertling I, Philipp M, Dvorak A, et al. Flupenthixol versus risperidone: subjective quality of life as an important factor for comliance in chronic schizophrenic patients. Neuropsychology. 2003;47:37-46.
31. Bobes J, Gutiérrez M, Gibert J, González MP, Herraiz L, Fernández A. Quality of life in schizophrenia: long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment. Eur Psychiatry. 1998;13:158-163.
32. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry. 2004;65:531-536.
33. Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL. The effectiveness of quatiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry. 2003;64:524-531.
34. Corrigan PW, Reinke RR, Landsberger SA, Charate A, Toombs GA. The effects of atypical antipsychotic medications on psychosocial outcomes. Schizophr Res. 2003;63:97-101.
35. Heinrichs DW, Hanlon TE, Carpenter WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388-398.
36. Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y. Quality of life outcomes of risperidone, olanzapine, and typical antipscyhotics among schizophrenia patients treated in routine clinical practice. A naturalistic comparative study. J Clin Psychopharmacol. 2004;24:582-591.
37. Haro JM, Edgell ET, Novick D et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the PanEuropean Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand. 2005;111:220-231.
38. Kilian R, Dietrich S, Toumi M Angermeyer MC. Quality of life in persons with schizophrenia in out-patient treatment with first- or second-generation antipsychotics. Acta Psychiatr Scand. 2004;110:108-118.
39. Endicott J, Nee J, Harrison W, et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321-326.
40. Prieto L, Sacristán JA, Hormaechea JA, Casado A, Badía X, Gómez JC. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin. 2003;20:827-835.
41. Lehman AF. A Quality of Life Interview for the chronically mentally ill (QOLI). Eval Prog Planning. 1988;11:51-62.
42. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
43. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry. 1992;160(suppl 17):46-53.
44. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry. 1993;150:1630-1638.
45. Ware JE, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). Med Care. 1992;30:473-483.
46. Giner J, Ibáñez E, Baca E, Bobes J, Leal C, Cervera S. Desarrollo del Cuestionario Sevilla de Calidad de Vida (CSCV). Actas Luso-Esp Neurol Psiquiatr. 1997;25(supl. 2):11-23.
47. Naber D. A self-rating to measure subjective effects of neuroleptic drug relationships to objective psychopathology, quality of life, compliance, and other clinical variables. Int Clin Psychopharmacol. 1995;10(suppl. 3):133-138.
48. Heinisch M, Ludwig M, Bullinger M. Psychometric testing of the "Münchner Lebensqualitäts Dimensionen Liste (MLDL). In: Bullinger M, Ludwig M, Steinbüchel V, eds. Lebensqualität bei Kardiovaskulären Erkrankungen. Göttingen, Toronto, Zürich: Hogrefe Verlag für Psychologie, 1991.
49. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment. Psychol Med. 1998;28:551-558.
50. Andreasen NC. PSYCH-BASE. Iowa City, Ia:The University of Iowa; 1989.
51. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders. Clinical descriptions and diagnostic guidelines. Geneva, Switzerland: World Health Organization; 1992.
52. Hellewell JS. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry. 1999;60(suppl 23):14-19.
53. Larson EB, Gerlach J. Subjective experience of treatment, side-effects, mental state and quality of life in cronic schizophrenic and out-patients treated with depot neuropleptics. Acta Psychiatr Scand. 1996;93:381-388.
54. Franz M, Lis S, Pluddemann K, Gallhofer G. Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry. 1997;170:422-425.
55. Larsen EB, Gerlach J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand. 1996;93:381-388.
56. Kaneda Y. The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with schizophrenia. Clinical Neuropharmacology. 2003;26:182-184.
57. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatric Services. 2003;54:565-567.
58. Strassnig M, Brar JS, Ganguli R. Body mass index and quality of life in community-dwelling patients with schizophrenia. Schizophr Res. 2003;62:73-76.
59. Meyer JM, Nasrallah HA, McEvoy JP, et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. Schizophr Res. 2005;80:9-18.
60. Olfson M, Uttaro T, Carson WH, Tafesse E. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry. 2005;66:331-338.
61. Dupuy H. The Psychological General Well-Being (PGWB) Index. In: Wenger N, Mattson M, Furberg C, et al, eds. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. Greenwich, CT: Le Jacq; 1984.
62. Wilkinson G, Hesdon B, Wild D, et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry. 2000;177:42-46.
63. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33:731-745.
64. Katschnig H. How useful is the concept of quality of life in Psychiatry? In: Katschnig H, Freeman H, Sartorius N, eds. Quality of Life in Mental Disorders. Chichester, UK: John Wiley & Sons Ltd; 2005:3-17.